NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours

NCT00750841

Active Not RecruitingPhase 1

Sponsor: AstraZeneca

Conditions: Solid Tumors

Interventions: cediranib

Countries: Canada, United Kingdom

Phase I, open study to assess the effect of rifampicin, a marketed drug, on how the body handles the experimental drug cediranib in patients with advanced cancer.

Eligibility overview

Sex: ALL

Age: 18 Years to 130 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Written informed consent
* Prostate cancer), which is refractory to standard therapies or for which no standard therapy exists.
* Estimated life expectancy of at least 8 weeks
* WHO performance status (PS) 0-2.

Exclusion Criteria:

* Unstable brain/meningeal metastases
* Biochemistry/haematology results outside of required ranges
* History of significant GI impairment
* Inadequate bone marrow reserve

Locations (6)

Edmonton, Alberta, Canada
Montreal, Quebec, Canada
Dundee, United Kingdom
Glasgow, United Kingdom
London, United Kingdom
London, United Kingdom